Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis.

ABSTRACT:

Background

Inflammatory bowel disease (IBD) is a complex autoimmune disorder, although some medications are available for its treatment. However, the long-term efficacy of these drugs remains unsatisfactory. Therefore, there is a need to develop novel drug targets for IBD treatment.

Methods

We conducted two-sample Mendelian randomization (MR) analysis using Genome-Wide Association Study (GWAS) data to assess the causal relationships between plasma proteins and IBD and its subtypes. Subsequently, the presence of shared genetic variants between the identified plasma proteins and traits was explored using Bayesian co-localization. Phenome-wide MR was used to evaluate evaluated adverse effects, and drug target databases were examined for therapeutic potential.

Results

Usi

SUBMITTER: Fan JC 

PROVIDER: S-EPMC11485038 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature